Brief: Elicera Enters Agreement With Prominent US Cancer Center
March 6 (Reuters) - Elicera Therapeutics AB ELIC.ST :
* ENTERS AGREEMENT WITH PROMINENT US CANCER CENTER TO
EVALUATE THE
USE OF ITANK IN T-CELL RECEPTOR THERAPIES
Source text for Eikon: ID:nWkr1SBYFG
Further company coverage: ELIC.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Elicera Therapeutics AB
See all newsBrief: Elicera Therapeutics Completes Phase I Part Of Carma Study
Brief: Elicera Therapeutics Gets Medical Products Agency Approval To Advance CARMA Study
Brief: Elicera Gets Clearance To Use Highest ELC-301 Dose Ahead Of Phase IIa
Brief: Elicera Gets First Patent Allowance For ELC-201
Brief: Elicera Receives Notice Of Allowance For U.S. Patent Application